Leerink Partnrs Issues Positive Outlook for BBIO Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Research analysts at Leerink Partnrs upped their Q3 2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a note issued to investors on Tuesday, October 14th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($0.78) for the quarter, up from their prior forecast of ($0.83). The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($3.38) EPS, FY2026 earnings at ($1.11) EPS and FY2028 earnings at $4.41 EPS.

Other research analysts have also issued research reports about the company. Piper Sandler lifted their target price on BridgeBio Pharma from $63.00 to $68.00 and gave the stock an “overweight” rating in a research report on Monday, July 14th. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of BridgeBio Pharma in a research report on Monday, September 15th. UBS Group lifted their target price on BridgeBio Pharma from $72.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Wells Fargo & Company lifted their target price on BridgeBio Pharma from $67.00 to $76.00 and gave the stock an “overweight” rating in a research report on Monday, June 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $95.00 target price on shares of BridgeBio Pharma in a research report on Tuesday, July 29th. Sixteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $65.06.

BridgeBio Pharma Trading Down 2.8%

Shares of BBIO opened at $55.03 on Thursday. The firm has a market cap of $10.52 billion, a price-to-earnings ratio of -13.45 and a beta of 1.36. The stock has a 50 day moving average of $51.82 and a 200-day moving average of $43.45. BridgeBio Pharma has a 52 week low of $21.72 and a 52 week high of $57.49.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Tuesday, August 5th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The firm had revenue of $110.57 million during the quarter, compared to the consensus estimate of $98.46 million. The company’s quarterly revenue was up 4999.9% on a year-over-year basis. During the same period last year, the firm posted ($0.39) EPS.

Insiders Place Their Bets

In related news, CEO Neil Kumar sold 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 8th. The stock was sold at an average price of $54.78, for a total value of $2,191,200.00. Following the sale, the chief executive officer owned 855,686 shares of the company’s stock, valued at approximately $46,874,479.08. This trade represents a 4.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Charles J. Homcy sold 50,000 shares of BridgeBio Pharma stock in a transaction on Monday, August 11th. The shares were sold at an average price of $48.00, for a total value of $2,400,000.00. Following the sale, the director directly owned 916,674 shares in the company, valued at $44,000,352. The trade was a 5.17% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 597,913 shares of company stock worth $29,034,227. 18.20% of the stock is currently owned by insiders.

Institutional Trading of BridgeBio Pharma

Several hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC grew its holdings in shares of BridgeBio Pharma by 28.6% during the third quarter. GAMMA Investing LLC now owns 1,020 shares of the company’s stock valued at $53,000 after buying an additional 227 shares in the last quarter. Steward Partners Investment Advisory LLC grew its holdings in shares of BridgeBio Pharma by 22.3% during the second quarter. Steward Partners Investment Advisory LLC now owns 1,250 shares of the company’s stock valued at $54,000 after buying an additional 228 shares in the last quarter. Gabelli Funds LLC grew its holdings in shares of BridgeBio Pharma by 0.3% during the second quarter. Gabelli Funds LLC now owns 73,750 shares of the company’s stock valued at $3,185,000 after buying an additional 250 shares in the last quarter. First Bank & Trust grew its holdings in shares of BridgeBio Pharma by 3.9% during the second quarter. First Bank & Trust now owns 8,822 shares of the company’s stock valued at $381,000 after buying an additional 329 shares in the last quarter. Finally, Main Management ETF Advisors LLC grew its holdings in shares of BridgeBio Pharma by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 22,723 shares of the company’s stock valued at $981,000 after buying an additional 372 shares in the last quarter. Institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.